派林生物 市值管理制度 派斯双林生物制药股份有限公司市值管理制度 1 第一章 总 则 第一条 为加强派斯双林生物制药股份有限公司（以下简称"公司"）市值管理 工作，进一步规范公司的市值管理行为，切实推动提升公司投资价值，更好地维护公 司、投资者及其他利益相关者的合法权益，依据《中华人民共和国公司法》《中华人 民共和国证券法》《上市公司监管指引第 10 号——市值管理》《深圳证券交易所股 票上市规则》等其他有关法律法规，制定本制度。 第二条 本制度所称市值管理，是指公司以提高公司质量为基础，为提升投资者 回报能力和水平而实施的战略管理行为。 第二章 市值管理的目的与基本原则 第三条 市值管理主要目的是通过充分合规的信息披露，增强公司透明度，引导 公司的市场价值与内在价值趋同，同时利用资本运作、权益管理、投资者关系管理等 手段，使公司价值得以充分实现，建立稳定和优质的投资者基础，获得长期的市场支 持，从而达到公司整体利益最大化和股东财富增长并举的目标。 第四条 公司在开展市值管理过程中，应当牢固树立回报股东意识，积极采取措 施保护投资者尤其是中小投资者利益，诚实守信、规范运作、专注主业、稳健经营， 推动经营水平和 ...

派斯双林生物制药股份有限公司 2024 年度独立董事述职报告 本人作为派斯双林生物制药股份有限公司（以下简称"公司"）2024 年度的独立董 事，严格按照《公司法》《证券法》《上市公司独立董事管理办法》《深圳证券交易所股票 上市规则》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》 《公司章程》及公司《独立董事工作制度》等有关规定，恪尽职守，勤勉尽责，充分发 挥独立董事的作用，切实维护公司整体利益、维护全体股东尤其是中小股东合法权益。 现将 2024 年度本人履行职责情况述职如下： 一、 基本情况 1．独立董事基本情况 汪文祺，中国国籍，无境外永久居留权，男，1987年生，硕士学位。2023年10月25 日至今任公司独立董事。2008年大学本科毕业于上海电力学院管理学专业，2011年取得 上海财经大学经济学硕士学位。曾任立信会计师事务所（特殊普通合伙）高级经理、中 汇会计师事务所（特殊普通合伙）上海分所高级经理。现任公司独立董事，上海立达联 合会计师事务所项目经理。 2．关于独立性自查情况 | 独立董事姓名 | 任职情况 | 报告期内应出 | 亲自出席 | 委托出席 | 缺席 | 列席股东 ...

派斯双林生物制药股份有限公司 2024 年度独立董事述职报告 本人作为派斯双林生物制药股份有限公司（以下简称"公司"）2024 年度的独立董 事，严格按照《公司法》《证券法》《上市公司独立董事管理办法》《深圳证券交易所股票 上市规则》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》 《公司章程》及公司《独立董事工作制度》等有关规定，恪尽职守，勤勉尽责，充分发 挥独立董事的作用，切实维护公司整体利益、维护全体股东尤其是中小股东合法权益。 现将 2024 年度本人履行职责情况述职如下： 一、 基本情况 1．独立董事基本情况 刘俊，中国国籍，无境外永久居留权，女，1985年出生，硕士学位。2023年12月11 日至今任公司独立董事。2011年硕士毕业于重庆大学经济法专业。曾任黑龙江省小额贷 款公司协会调研员，郑州宇通重工有限公司法务，安邦财产保险股份有限公司黑龙江分 公司合规负责人，黑龙江珍宝岛药业股份有限公司法务经理。现任公司独立董事，黑龙 江大地律师事务所高级合伙人。 本人认真审议了各项议案，履行了独立董事的忠实义务和勤勉义务。对公司董事会 审议的各项议案独立、客观、审慎的进行了表决，历次董 ...

二、前10名无限售条件股东持股情况 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 1.0200 | 0.8400 | 21.43 | 0.8035 | | 每股净资产（元） | 10.84 | 10.13 | 7.01 | 9.38 | | 每股公积金(元) | 6.51 | 6.54 | -0.46 | 6.53 | | 每股未分配利润(元) | 3.11 | 2.50 | 24.4 | 1.76 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 26.55 | 23.29 | 14 | 24.05 | | 净利润(亿元) | 7.45 | 6.12 | 21.73 | 5.87 | | 净资产收益率(%) | 9.65 | 8.58 | 12.47 | 8.90 | 三、分红送配方案情况 数据四舍五入，查看更多财务数据>> 10转3股派3.5元(含税) 一、主要会计数据和财务指标 前十大流通股东累计持有： 3081 ...

Financial Performance - The company's operating revenue for 2024 reached ¥2,654,684,638.93, representing a 14.00% increase compared to ¥2,328,723,280.44 in 2023[17] - The net profit attributable to shareholders for 2024 was ¥745,320,757.41, a 21.76% increase from ¥612,111,043.76 in 2023[17] - The net profit after deducting non-recurring gains and losses was ¥683,191,198.14, up 21.01% from ¥564,595,832.55 in 2023[17] - The basic earnings per share for 2024 was ¥1.02, reflecting a 21.43% increase from ¥0.84 in 2023[18] - The total assets at the end of 2024 amounted to ¥9,246,269,365.26, a 7.14% increase from ¥8,630,474,084.53 at the end of 2023[18] - The net assets attributable to shareholders increased to ¥7,924,650,751.55, a 6.68% rise from ¥7,428,649,258.06 in 2023[18] - The net cash flow from operating activities decreased by 52.61% to ¥321,790,406.27 from ¥679,006,330.60 in 2023[18] - The weighted average return on net assets for 2024 was 9.65%, an increase of 1.07 percentage points from 8.58% in 2023[18] Market Outlook - The global blood products market is projected to exceed USD 50 billion in 2024, with an expected growth to over USD 90 billion by 2030[27] - China's blood products market is anticipated to reach CNY 60 billion in 2024, with a forecasted growth to CNY 95 billion by 2030, indicating substantial growth potential[28] - The future market growth potential for the blood products industry in China is significant, with expectations for increased clinical application of immunoglobulin products and expanded insurance coverage for coagulation factor products[33] - The blood products industry in China is expected to exceed a market capacity of 100 billion yuan in the future, driven by economic development, aging population, and increased clinical demand[35] Company Strategy and Operations - The company has expanded its product offerings to a total of 11 varieties, positioning itself as the third-largest blood product company in China[36] - The company has established 38 plasma collection stations, ranking among the top three in the industry, and aims to exceed 1,400 tons of plasma collection by 2024[36] - The company is focused on both organic growth and external expansion to enhance its industry position and product capabilities[36] - The company plans to expand its production capacity to over 3,000 tons annually, supporting future growth[44] - The company has a strategic partnership with Xinjiang Deyuan to enhance plasma sourcing, which is expected to support its growth strategy over the next eight years[36] Research and Development - The company has a total of 62 authorized patents and is actively developing over 10 new products[47][48] - The company is advancing several R&D projects, including a new generation of intravenous human immunoglobulin, which received clinical trial approval in May 2024[70] - The capitalized R&D investment increased significantly by 199.69% to ¥42,126,645.19, representing 43.29% of total R&D investment, driven by the clinical trial phase of the new immunoglobulin project[70] Risk Factors - The company has outlined potential risks in its future outlook, emphasizing the need for investors to be aware of investment risks[4] - The supply of raw materials, specifically human plasma, is a critical risk factor, with over 60% of human albumin in the market relying on imports[108] - The company faces risks related to national regulatory policies, which may impact production and operational dynamics in the blood product industry[106] Corporate Governance - The company adheres to legal regulations and has established a sound corporate governance structure, ensuring effective checks and balances among decision-making, supervisory, and executive bodies[119] - The company maintains independence from its controlling shareholder in terms of personnel, assets, finance, and operations, ensuring independent accounting and risk management[122] - The company has a dedicated board secretary responsible for information disclosure and investor relations management, ensuring timely and accurate information dissemination[120] Shareholder Returns - The company plans to distribute a cash dividend of ¥3.5 per 10 shares, with no bonus shares issued[4] - The total cash dividends for 2024 and the mid-year distribution combined amount to ¥365,537,456.55, representing 49.04% of the net profit attributable to shareholders[170] - The proposed cash dividend for 2024 is ¥3.5 per 10 shares, totaling ¥255,876,219.55, which is 34.33% of the net profit attributable to shareholders[170] Employee and Management Structure - The total number of employees at the end of the reporting period is 2,635, with 2,622 from major subsidiaries and 13 from the parent company[156] - The company has established a comprehensive training system to enhance employee skills and knowledge, focusing on regulatory, management, and technical training[159] - The company has implemented a dynamic salary management system that adjusts employee compensation based on various factors including performance and market conditions[158] Environmental Compliance - The company strictly adheres to environmental protection laws and regulations, ensuring compliance with various environmental standards[197] - No pollution incidents or disputes occurred during the reporting period, and the company has not faced administrative penalties for environmental violations[198] - The company obtained a new pollutant discharge permit valid until November 19, 2028, demonstrating ongoing compliance with environmental regulations[199]

Financial Performance - The company's revenue for Q1 2025 was ¥374,649,641.98, a decrease of 14.00% compared to ¥435,640,719.29 in the same period last year[6] - Net profit attributable to shareholders was ¥89,089,215.65, down 26.95% from ¥121,948,626.85 year-on-year[6] - Basic earnings per share decreased by 29.41% to ¥0.12 from ¥0.17 in the same period last year[6] - Net profit for the period was ¥88,939,547.68, down from ¥121,869,775.56, representing a decline of approximately 27%[22] - Total operating revenue decreased to ¥374,649,641.98 from ¥435,640,719.29, a decline of approximately 14%[21] - Total operating costs reduced to ¥276,480,817.30 from ¥297,485,500.88, reflecting a decrease of about 7%[21] Cash Flow - The net cash flow from operating activities was -¥115,839,348.29, representing a decline of 123.36% compared to -¥51,862,351.40 in the previous year[6] - Total cash inflow from operating activities was 504,109,212.86 CNY, down 10.67% from 564,474,916.40 CNY in the previous period[25] - Cash outflow from operating activities totaled 619,948,561.15 CNY, slightly increased from 616,337,267.80 CNY in the previous period[25] - Cash flow from investment activities showed a net outflow of -546,717,554.17 CNY, worsening from -440,371,925.58 CNY in the previous period[25] - The net cash flow from financing activities was 8,119,220.71 CNY, a decline from 51,599,071.36 CNY in the previous period[25] - The ending cash and cash equivalents balance was 665,919,948.78 CNY, down from 987,647,622.30 CNY in the previous period[25] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥9,196,700,838.85, a decrease of 0.54% from ¥9,246,269,365.26 at the end of the previous year[6] - Total current assets at the end of the reporting period amount to 3,469,649,834.08 yuan, a decrease from 3,578,948,533.75 yuan at the beginning of the period[17] - Total liabilities decreased to ¥1,190,259,363.13 from ¥1,328,766,729.91, a reduction of about 10%[19] - Non-current assets totaled ¥5,727,051,004.77, up from ¥5,667,320,831.51, an increase of approximately 1%[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 29,271[14] - The largest shareholder, Qiongqing City Shengbang Yinghao Investment Partnership, holds 21.03% of shares, totaling 153,752,812 shares, with 123,002,200 shares pledged[14] - The second largest shareholder, Harbin Tongzhi Cheng Technology Development Co., Ltd., holds 10.99% of shares, totaling 80,381,128 shares, with 30,723,000 shares pledged[14] Production and Expansion - The company is expanding production capacity, with Harbin Paisfeico's capacity increasing to 1,600 tons and Guangdong Shuanglin's expected to reach 1,500 tons by mid-2025, totaling over 3,000 tons[6] - The company anticipates improved performance in 2025 due to the completion of capacity expansions, which will support sustainable growth[6] Research and Development - Research and development expenses were ¥10,126,449.49, down 51.47% from ¥20,864,588.50, mainly due to reduced material usage[12] - The company reported an increase in development expenditures to ¥131,852,297.21 from ¥109,769,448.82, an increase of approximately 20%[20] - The company is in the process of obtaining clinical trial approval for new indications through its wholly-owned subsidiary[16] Strategic Initiatives - The company has announced a strategic cooperation agreement, indicating potential market expansion[16] - The company plans to use idle raised funds for temporary liquidity support[16]

医药生物行业今日上涨2.03%，全天主力资金净流出6.86亿元，该行业所属的个股共476只，今日上涨的 有459只，涨停的有6只；下跌的有13只。以资金流向数据进行统计，该行业资金净流入的个股有192 只，其中，净流入资金超3000万元的有8只，净流入资金居首的是恒瑞医药，今日净流入资金1.29亿 元，紧随其后的是泰格医药、永安药业，净流入资金分别为6531.50万元、4910.80万元。医药生物行业 资金净流出个股中，资金净流出超5000万元的有6只，净流出资金居前的有派林生物、翰宇药业、天坛 生物，净流出资金分别为1.14亿元、9298.74万元、7631.74万元。（数据宝） 医药生物行业资金流入榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 600276 | 恒瑞医药 | 0.58 | 1.15 | 12892.29 | | 300347 | 泰格医药 | 0.67 | 2.46 | 6531.50 | | 002365 | 永安药业 | 6.10 | 27.61 | 4910.80 ...

Investment Rating - The report maintains a rating of "Buy" for the pharmaceutical and biotechnology industry [5]. Core Viewpoints - The report highlights the increasing external uncertainties following the US-China tariff conflict and expresses optimism towards domestic circulation and safe-haven assets in the pharmaceutical sector [2][20]. - The demand for blood products is relatively inelastic, and the recent tariff increases may lead to a short-term rise in imported albumin prices, benefiting domestic companies. The blood products industry is characterized by rigid demand and strategic resource attributes, suggesting a favorable competitive landscape for domestic alternatives [21]. - The report emphasizes the shift from "efficiency-first" to "safety-first" in supply chains, driven by the need for supply chain security, which may catalyze domestic replacements in high-end medical devices and scientific instruments [22][24]. Summary by Sections Market Review - Last week, the A-share pharmaceutical and biotechnology index rose by 1.20%, outperforming the CSI 300 index by 2.57 percentage points and the ChiNext index by 3.55 percentage points, ranking third among 31 sub-industries [1][16]. - The Hong Kong Hang Seng Medical Health Index increased by 1.32%, surpassing the Hang Seng Index by 3.49 percentage points [1][16]. Company Updates - Recent developments include the new listing application for SHR2554 tablets by Heng Rui Medicine and clinical application advancements for several products from Heng Rui Medicine and Lepu Biopharma [27]. Investment Strategy - The report suggests focusing on three main directions: policy support for hospital payments (innovative drugs and devices), expansion of public demand (blood products, home medical devices, weight loss drug supply chains), and an upward cycle for overseas payments (heparin, respiratory joint inspections) [24]. Key Company Profit Forecasts and Valuations - Key companies such as Mindray Medical, United Imaging, and Yuyue Medical are highlighted with projected earnings per share (EPS) and price-to-earnings (PE) ratios indicating a "Buy" recommendation [4]. Important Database Updates - The cumulative total number of hospital diagnoses showed a year-on-year increase of 13.29%, with significant growth in tertiary hospitals [30]. - The pharmaceutical manufacturing industry reported a year-on-year revenue decline of 3.4% for the first two months of 2025, with total revenue of 369.43 billion yuan [60].

Group 1: Policy Support for Pharmaceutical Innovation - Beijing encourages local production of innovative pharmaceuticals, supporting enterprises in importing significant drug and medical device varieties, and promoting the industrialization and large-scale application of innovative products [1] - Shenzhen offers financial incentives for innovative drugs that complete clinical trials and achieve domestic and international market entry, with rewards up to 30 million yuan based on clinical trial phases [2] Group 2: Company Developments - Heng Rui Medicine grants exclusive commercialization rights of its new drug SHR7280 to Germany's Merck, receiving an upfront payment of 15 million euros and potential milestone payments and sales royalties [3] - East China Pharmaceutical's subsidiary receives approval for clinical trials of DR30206, a novel antibody fusion protein targeting PD-L1, VEGF, and TGF-β, marking a significant advancement in its development [4] Group 3: Market Trends and Opportunities - Blood product stocks, including Wei Guang Bio and Pai Lin Bio, experience a surge due to the rigid demand for blood products and potential price increases from U.S. tariffs, benefiting domestic companies and presenting strategic opportunities for market share growth [6]

4月7日，上证指数下跌7.34%，深证成指下跌9.66%，创业板指下跌12.5%。盘后龙虎榜数据显示，共有 60只个股因当日异动登上龙虎榜，资金净流入最多的是宏景科技（301396.SZ），达2.04亿元。 据21投资通智能监测，32只个股龙虎榜出现了机构的身影，北向资金参与龙虎榜中的个股共涉及18只。 2.04亿资金抢筹宏景科技，9.45亿资金出逃中际旭创 60只上榜的龙虎榜个股中，30只个股被净买入，30只个股被净卖出。其中，资金净买入最多的是宏景科 技，达2.04亿元，占总成交金额的14.04%。宏景科技当日收盘下跌13.42%，换手率为34.73%。 | 名称 | 涨跌幅 | 龙虎榜净买 | 净买额占 | 换丰浓 | | | --- | --- | --- | --- | --- | --- | | | | 额(万元 | 总成交比 | | | | 宏景科技 | -13.42% | 20444 | 14.04% | 34.73% | 2家机构卖出,成功 | | | | | | | 率36.92% | | 凯美特气 | 9.99% | 17123 | 7.3% | 32.28% | 普通席位买入,成功 | ...